SCHEMBL6822071

SCHEMBL6822071

COc1ccc2c(C(C)=O)c(-c3ccccc3)nn2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
ATM Q13315 1/20 0.44
CSF1R P07333 1/20 0.44
FGFR1 P11362 1/20 0.44
FLT1 P17948 1/20 0.44
KDR P35968 1/20 0.44
CSNK1A1 P48729 1/20 0.44
CDK8 P49336 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
CDK5 Q00535 1/20 0.44
PRKCQ Q04759 1/20 0.44
LRRK2 Q5S007 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
DYRK1B Q9Y463 1/20 0.44
MAPT P10636 2/20 0.43
HTT P42858 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822005 0.81 EGFR (0.45) EGFRCSF1RFGFR1FLT1KDR
SCHEMBL682707 0.79 NPC1 (0.45) MAPTHTTMEN1KMT2AALDH1A1
SCHEMBL7665680 0.77 EGFR (0.61) EGFRCSF1RFGFR1FLT1KDR
SCHEMBL24320205 0.73 MEN1 (0.51) EGFRL3MBTL1MAPTMEN1KMT2A
SCHEMBL1936384 0.73 KMT2A (0.51) EGFRL3MBTL1MAPTHTTMEN1
SCHEMBL5216599 0.71 GABRP (0.43) L3MBTL1ATMMAPTMEN1KMT2A
SCHEMBL11976409 0.70
SCHEMBL4472139 0.70 PTGS1 (0.58) L3MBTL1ATMGSK3BMAPTMEN1
SCHEMBL8887875 0.70 MEN1 (0.51) L3MBTL1MAPTHTTMEN1KMT2A
SCHEMBL22147873 0.70 ALDH1A1 (0.42) L3MBTL1MAPTHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 EGFR 3229/4885L3MBTL1 2651/4885ATM 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.